Newswise — SRxA Strategic Pharmaceutical Advisors, a leading healthcare consulting, marketing and education firm, is pleased to announce that it has entered into an agreement with the Boards of Directors of the Eastern Allergy Conference (EAC) and the North American Rhinology & Allergy Conference (NARAC), to become the exclusive provider of rapid dissemination post-congress e-newsletters.
The Eastern Allergy Conference, an annual specialty meeting, was established in 1987. It is jointly sponsored and accredited by the American College of Allergy, Asthma and Immunology (ACAAI) and involves active participation of the major State and Regional Allergy Societies. The next scheduled Eastern Allergy Conference will take place June 2-5, 2011, in Palm Beach Florida.
The inaugural annual North American Rhinology & Allergy Conference will take place February 3-6, 2011, in Puerto Rico. This meeting will bring together Otolaryngologists and Allergists to discuss the most current information regarding the management of diseases of the nose and airways.
While the scientific data presented at both conferences will be published several months later in peer-reviewed journals, Russell A. Settipane, MD, the Executive Director of both Conferences, saw the need for a more rapid dissemination of the key data to allergy and otolaryngology communities.
SRxA and its team of Allergy and ENT Clinical Advisors will fulfill this need by developing, producing and publishing electronic newsletters featuring highlights of the congress within 2 weeks of each meeting. Each newsletter will feature a blend of scientific session reviews, “hot topic” discussions, key takeaway messages, news from the exhibit hall, and other pertinent information. The newsletters will be distributed electronically to a target audience of more than 3,000 Allergists and 6,000 Otolaryngologists based in the United States. Both e-newsletters will be supported by multiple members of the industry, and all commercial sponsors will be prominently acknowledged in the publications.
“These electronic newsletters will be a perfect complement to the peer-reviewed manuscripts, originating from the conferences, that we publish in Allergy and Asthma Proceedings and the American Journal of Rhinology and Allergy. Some of the Journal's most popular articles have resulted from the excellent presentations delivered at the EAC, and we are anticipating similar from NARAC. SRxA was the natural choice for a partner in this endeavor, because of the depth of their knowledge and expertise in Allergy and Otolaryngology” said Dr. Settipane.
“We are delighted to work with Dr. Settipane and his team to develop and produce a unique vehicle that will distribute pertinent information in a timely fashion to the medical communities they serve” commented Christos Efessiou, PhD, SRxA’s Chief Executive Officer.
SRxA operates on a unique business model that utilizes independent clinical teams of national and international Key Opinion Leaders who advise pharmaceutical and medical device clients in research, clinical, regulatory, education and business matters. SRxA advisory groups focus in key therapeutic areas such as Allergy, Otolaryngology, Pulmonary Diseases, Respiratory Medicine (Europe), Ophthalmology, Health Outcomes, Reproductive Endocrinology and Genetics, Aesthetics, and Behavioral Health. The company is headquartered in Washington, DC with offices in London and Hong Kong.
RSS